Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
Vaccine
; 24(42-43): 6526-33, 2006 Oct 30.
Article
en En
| MEDLINE
| ID: mdl-16842888
ABSTRACT
We assessed the safety and immunogenicity of prime-boost vectors encoding the Plasmodium falciparum circumsporozoite (CS) protein expressed either in the attenuated fowl-pox virus (FP9) or modified vaccinia virus Ankara (MVA). Thirty-two adult Gambians in groups of four to eight received one, two or three doses of FP9 CS and/or MVA CS. No serious adverse event was observed following vaccination. The most immunogenic regimen was two doses of FP9 followed by a single dose of MVA 4 weeks later (an average of 1000 IFN-gamma spot forming units/million PBMCs). This level of effector T-cell responses appears higher than that seen in previously reported studies of CS-based candidate malaria vaccines.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Antiprotozoarios
/
Vacunas contra la Malaria
Límite:
Adult
/
Animals
/
Humans
/
Male
País/Región como asunto:
Africa
Idioma:
En
Revista:
Vaccine
Año:
2006
Tipo del documento:
Article
País de afiliación:
Gambia
Pais de publicación:
HOLANDA
/
HOLLAND
/
NETHERLANDS
/
NL
/
PAISES BAJOS
/
THE NETHERLANDS